International campaigners urge UK to allow ‘3-parent’ IVF babies

The process, still only at the research stage in Britain and the United States, involves intervening in the fertilisation process to remove faulty mitochondrial DNA, which can cause inherited conditions such as fatal heart problems, liver failure, brain disorders, blindness and muscular dystrophy. Britain last February set out draft legislation that, if passed, would make it the first country to allow the technique. In their letter, groups including the U.S.-based United Mitochondrial Disease Foundation, the Australian Mitochondrial Disease Foundation and groups from France, Germany, Britain and Spain, described mitochondrial disease as “unimaginably cruel”. The issue of mitochondrial donation has been scrutinised by several expert panels in Britain, including the Human Fertilisation and Embryology Authority and the Nuffield Council on Bioethics.
Go to Source

Antibiotics firm Motif Bio to tap UK market for cash

Motif Bio, which is working on a range of antibiotics, is planning to raise at least 4 million pounds ($6 million) – and potentially up to 16 million – through a stock market listing in London. Motif Bio said it was in talks with investors ahead its move to list on the AIM market as it seeks funding to advance its experimental drugs. Motif Bio, which is led by former Merck executive and one-time vet Graham Lumsden, is buying rights to iclaprim through the purchase of U.S. firm Nuprim in a deal that will be completed once the company lists on AIM. Motif Bio believes it can get the drug approved by addressing certain shortfalls in the original development program.
Go to Source

1 51 52 53